Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07776964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07776964 · ClinicalTrials.gov record · last posted 2026-08-20

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment. Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers. Participants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.
Trial Details
NCT Number NCT07776964
Lead Sponsor University of Minnesota
Collaborators: Boston Scientific Corporation
Conditions Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma
Enrollment 72 participants
Start Date 2026-09-01
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-20